PMID- 34413777
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210821
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Oroxylin a Attenuates Limb Ischemia by Promoting Angiogenesis via Modulation of 
      Endothelial Cell Migration.
PG  - 705617
LID - 10.3389/fphar.2021.705617 [doi]
LID - 705617
AB  - Oroxylin A (OA) has been shown to simultaneously increase coronary flow and 
      provide a strong anti-inflammatory effect. In this study, we described the 
      angiogenic properties of OA. OA treatment accelerated perfusion recovery, reduced 
      tissue injury, and promoted angiogenesis after hindlimb ischemia (HLI). In 
      addition, OA regulated the secretion of multiple cytokines, including vascular 
      endothelial growth factor A (VEGFA), angiopoietin-2 (ANG-2), fibroblast growth 
      factor-basic (FGF-2), and platelet derived growth factor BB (PDGF-BB). 
      Specifically, those multiple cytokines were involved in cell migration, cell 
      population proliferation, and angiogenesis. These effects were observed at 3, 7, 
      and 14 days after HLI. In skeletal muscle cells, OA promoted the release of VEGFA 
      and ANG-2. After OA treatment, the conditioned medium derived from skeletal 
      muscle cells was found to significantly induce endothelial cell (EC) 
      proliferation. OA also induced EC migration by activating the Ras homolog gene 
      family member A (RhoA)/Rho-associated coiled-coil kinase 2 (ROCK-II) signaling 
      pathway and the T-box20 (TBX20)/prokineticin 2 (PROK2) signaling pathway. In 
      addition, OA was able to downregulate the number of macrophages and neutrophils, 
      along with the secretion of interleukin-1beta, at 3 days after HLI. These results 
      expanded current knowledge about the beneficial effects of OA in angiogenesis and 
      blood flow recovery. This research could open new directions for the development 
      of novel therapeutic intervention for patients with peripheral artery disease 
      (PAD).
CI  - Copyright (c) 2021 Zhang, Chen, Li, Shi, Wang, Yang, Fang, Leng, Sun, Li, Xue, Gao 
      and Wang.
FAU - Zhang, Lusha
AU  - Zhang L
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Chen, Lu
AU  - Chen L
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
AD  - Tianjin Key Laboratory of Traditional Chinese Medicine Pharmacology, Tianjin, 
      China.
AD  - Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin, China.
AD  - Institute of Traditional Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tianjin, China.
FAU - Li, Chunxiao
AU  - Li C
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
AD  - Tianjin Key Laboratory of Traditional Chinese Medicine Pharmacology, Tianjin, 
      China.
FAU - Shi, Hong
AU  - Shi H
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
AD  - Tianjin Key Laboratory of Traditional Chinese Medicine Pharmacology, Tianjin, 
      China.
AD  - Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin, China.
AD  - Institute of Traditional Chinese Medicine, Tianjin University of Traditional 
      Chinese Medicine, Tianjin, China.
FAU - Wang, Qianyi
AU  - Wang Q
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Yang, Wenjie
AU  - Yang W
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Fang, Leyu
AU  - Fang L
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Leng, Yuze
AU  - Leng Y
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Sun, Wei
AU  - Sun W
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Li, Mengyao
AU  - Li M
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Xue, Yuejin
AU  - Xue Y
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
FAU - Gao, Xiumei
AU  - Gao X
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
AD  - Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin, China.
FAU - Wang, Hong
AU  - Wang H
AD  - State Key Laboratory of Component-based Chinese Medicine, Tianjin University of 
      Traditional Chinese Medicine, Tianjin, China.
AD  - Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry 
      of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
AD  - Tianjin Key Laboratory of Traditional Chinese Medicine Pharmacology, Tianjin, 
      China.
AD  - Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin, China.
AD  - School of Integrative Medicine, Tianjin University of Traditional Chinese 
      Medicine, Tianjin, China.
LA  - eng
PT  - Journal Article
DEP - 20210730
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8370028
OTO - NOTNLM
OT  - angiogenesis
OT  - endothelial cells
OT  - hind limb ischemia
OT  - inflammation
OT  - migration
OT  - oroxylin A
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/08/21 06:00
MHDA- 2021/08/21 06:01
PMCR- 2021/07/30
CRDT- 2021/08/20 07:01
PHST- 2021/05/05 00:00 [received]
PHST- 2021/07/16 00:00 [accepted]
PHST- 2021/08/20 07:01 [entrez]
PHST- 2021/08/21 06:00 [pubmed]
PHST- 2021/08/21 06:01 [medline]
PHST- 2021/07/30 00:00 [pmc-release]
AID - 705617 [pii]
AID - 10.3389/fphar.2021.705617 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Jul 30;12:705617. doi: 10.3389/fphar.2021.705617. 
      eCollection 2021.